Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX1)

Next Previous
Trial Profile

A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX1)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aztreonam (Primary)
  • Indications Bronchiectasis; Gram-negative infections
  • Focus Therapeutic Use
  • Acronyms AIR-BX1
  • Sponsors Gilead Sciences

Most Recent Events

  • 07 Apr 2020 Results of post hoc analysis of AIR-BX1 and AIR-BX2 studies published in the European Respiratory Journal
  • 12 May 2019 Results of a post-hoc analysis of AIR-BX1 and AIR-BX2 trials assessing the airway bacterial load and inhaled antibiotic response in Bronchiectasis, published in the American Journal of Respiratory and Critical Care Medicine
  • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top